Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahman, Md. A.
Right arrow Articles by Nagasue, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahman, Md. A.
Right arrow Articles by Nagasue, N.
Clinical Cancer Research Vol. 7, 1325-1332, May 2001
© 2001 American Association for Cancer Research

Molecular Oncology

Coexpression of Inducible Nitric Oxide Synthase and COX-2 in Hepatocellular Carcinoma and Surrounding Liver

Possible Involvement of COX-2 in the Angiogenesis of Hepatitis C Virus-positive Cases

Md. Atiqur Rahman1, Dipok Kumar Dhar, Emi Yamaguchi, Seiji Maruyama, Takashi Sato, Hikota Hayashi, Takashi Ono, Akira Yamanoi, Hitoshi Kohno and Naofumi Nagasue

Second Department of Surgery, Shimane Medical University, Izumo 693-8501, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) has been reported to be responsible for enhanced tumor growth and angiogenesis in various tumors. However, the relationships between tumor vascularity and COX-2 and iNOS expression have not been evaluated in hepatocellular carcinoma (HCC). In this study, we examined the expression of iNOS and COX-2 and microvessel density (MVD) by immunohistochemical staining in 100 tissue sections collected from HCC patients. iNOS expression was significantly higher in hepatitis C virus (HCV)-positive HCCs (P = 0.011). COX-2 expression was significantly correlated with iNOS expression (P = 0.046) and tumor MVD (P = 0.011) in HCV-positive HCCs. iNOS expression was neither correlated with MVD nor had any influence on patient survival; however, combined negative expression of iNOS and COX-2 had a significant impact on patient survival (P = 0.041 and 0.018, log-rank test for overall and recurrence-free survival rate, respectively). The present findings suggest that combined expression of iNOS and COX-2 may play an important role in prognosis of HCV-positive HCC patients and that this could be partially attributable to modulation of angiogenesis by COX-2.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
NO, a small potent lipophilic gas with divergent biological activities, seems to play important roles in modulating tissue injury and carcinogenesis (1) . Three distinct forms of NOS2 catalyze the formation of NO. Endothelial NOS and neuronal NOS are constitutively expressed in different tissues, whereas iNOS is related to a high-output pathway and is responsible for various pathological processes (2) . Although increased iNOS expression has been demonstrated in colon (3) , prostate (4) , and bladder cancer (5) , its exact function in the tumor biology is not yet clear.

COX, constitutively expressed COX-1, and inducible COX-2, are the rate-limiting enzymes for production of prostanoids (prostaglandins and thromboxanes) from arachidonic acid (6) . COX-2 has recently been categorized as an immediate-early gene associated with inflammation (7) , cellular growth (8) , differentiation (9) , prevention of apoptosis (9) , and tumorigenesis (3) . It has also been reported that COX-2 induces angiogenesis, which is essential for tumor growth (10) . Increased prostaglandin production and enhanced release of angiogenic growth factor by COX-2 may induce neovascularization (3 , 8) .

Evidence suggests that NO produced by iNOS enhances the activity of COX-2 (11) . Expression of both iNOS and COX-2 has been reported to be increased in Barrett’s esophagus and esophageal adenocarcinomas and also in Helicobacter pylori-induced gastritis (12 , 13) . NO and COX-2 have carcinogenic effects achieved either directly or by producing mediators that regulate cellular growth (10 , 14) . These effects may be mediated by the formation of peroxinitrite and prostanoids and involve "cross-talk" between the two enzyme systems (15) . To determine the roles of iNOS and COX-2 in HCC, we compared their expressions by the immunohistochemical method.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and Tissue Samples.
One hundred patients (77 males, 23 females) with HCC undergoing curative hepatectomy (segmental or lobar resection) between 1989 and 1997 were included in this study. The tissue samples were fixed in 10% neutral formalin and subjected to histopathological examination. None of the patients received pre- or postoperative adjuvant chemo- or radiotherapy. The age of the patients ranged from 36 to 78 years (62.8 ± 8.7 years, mean ± SD). Tumor size varied from 1.2 to 18.5 cm in diameter. Of the 100 patients, 55 were positive for antibody to HCV (anti-HCV). Preoperative ultrasonography, computed tomography scan, and angiography were performed routinely for all patients. Our criteria for definition of curability were described previously (16) . All patients received follow-up at regular time intervals. Recurrence after surgery was diagnosed by serum AFP level, ultrasonography, computed tomography scan, and angiography. The criteria for histological study were described previously (17) .

Immunohistochemical Staining of iNOS, COX-2, and CD34.
Tumor samples free of necrosis or hemorrhage on macroscopic inspection were selected for histology. Samples were routinely fixed in 10% formalin and subsequently embedded in paraffin. Serial sections 4-µm thick were prepared from paraffin blocks. Sections were deparaffinized and hydrated by sequential immersion in xylene and graded alcohol solutions. The sections were then incubated in 3% H2O2 for 30 min to block the endogenous peroxidase activity. For iNOS staining, slides were incubated with 2% skim milk for 10 min. Slides were treated with normal serum obtained from the same species in which the secondary antibody was developed for 30 min to block nonspecific staining. Subsequently, slides were incubated with primary antibodies [anti-iNOS (WAKO Pharmaceuticals Ltd., Osaka, Japan) at 1:500 dilution for 60 min at room temperature; anti-COX-2 (Cayman Chemical, Ann Arbor, MI) at 1:300 dilution overnight at 4°C; and anti-CD34 (Dako, Glostrup, Denmark) at 1:50 dilution for 1 h at room temperature], as appropriate. Immunostaining was performed according to the avidin-biotin peroxidase complex method by a commercially available kit [Histofine, SAB-PO(R); Nichirei Corporation, Tokyo, Japan]. Slides were treated with a biotin-conjugated secondary antibody for 30 min followed by incubation with peroxidase-conjugated streptavidin for 30 min at room temperature. All steps were followed by washing in PBS. Peroxidase activity was detected by incubating the samples with 3-amino-9-ethylcarbazol (Histofine, Tokyo, Japan). Finally, the sections were counterstained with hematoxylin. For CD34 staining, counter staining was not done.

Evaluation of iNOS and COX-2 Expression.
The degree of staining was categorized by the extent and intensity of the staining. Two independent observers screened all sections as a semiquantitative evaluation of iNOS and COX-2 immunostaining. The immunoreactive score was determined by the sum of extension and intensity as reported previously (18) The intensity of staining was scored on a scale of 0 to 3, in which 0 = negative staining, 1 = weakly positive staining, 2 = moderately positive staining, and 3 = strongly positive staining. The extent of positivity ("extent of distribution" of positive cells) was estimated on a scale of 0 to 4, in which 0 = negative, 1 = positive staining in 1–25% of cells, 2 = positive staining in 26–50%; 3 = positive staining in 51–75%; and 4 = positive staining in 76–100%. The combined staining score (extension + intensity) >=3 was considered as positive staining.

Quantitation of MVD.
Because of the technical difficulty in counting linearly immunostained sinusoids, we used an image analysis system to assess the MVD as a percentage of the endothelial area. Because the immunoreactivity of CD34 showed slight heterogeneity within the same tumor, the five most highly vascularized areas (hot spots) were selected in x200 magnification fields. The images were scanned with a Olympus CCD camera and stored on a computer for subsequent analysis. On the computer screen image, the background color was subtracted and the 3,3'-diaminobenzidine-stained area was evaluated using the NIH (Bethesda, MD) image analysis system (19) . A MVD value >=3 (median value of the MVD) was considered high MVD.

Statistical Analysis.
Correlation between factors was evaluated using the Spearman rank correlation coefficient test. Survival rates were obtained by the Kaplan-Meier method, and the differences were compared by the log-rank and Wilcoxon tests. Significance differences between categorical variables were compared by the {chi}2 test or Fisher’s exact probability test when appropriate. Continuous variables were compared by the Mann-Whitney U test. Multivariate analyses was performed by the Cox proportional hazards regression analysis using StatView 4.11 (Abacus Concepts, Inc., Berkeley, CA) software on a Macintosh computer. P < 0.05 was considered significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
iNOS Expression.
iNOS immunoreactivity was observed mainly in the hepatocytes, showing a predominant cytoplasmic staining, with the positive liver cells distributed in both the tumor tissue and surrounding liver (Fig. 1, A and B)Citation . iNOS expression was not observed in liver-infiltrating mononuclear cells, vascular endothelium, or sinusoidal lining cells. iNOS immunoreactive score was significantly higher in the surrounding liver (P = 0.011) in HCV-positive HCC cases (Table 1)Citation . We found no correlation between tumor iNOS expression and clinicopathological factors in all cases (n = 100; data not shown).



View larger version (134K):
[in this window]
[in a new window]
  		Fig. 1. Representative sections showing immunohistochemical expression of iNOS (A, surrounding liver; B, tumor; magnification, x40), COX-2 (C, surrounding liver; D, tumor; magnification, x40), and CD34 (E, tumor tissue without any counter staining) in HCC.

 

View this table:
[in this window]
[in a new window]
  		Table 1 Relationship between iNOS expression and clinicopathological factors in HCC (n = 100)

 
COX-2 Expression.
In immunohistochemical analysis, cytoplasmic staining for COX-2 was observed in both tumor cells and nontumorous connective tissue cells, including those of sinusoidal endothelial cells (Fig. 1, C and D)Citation . We found no correlation between tumor COX-2 expression and clinicopathological factors when evaluated in all HCC cases (data not shown). In HCV-positive HCC cases, the COX-2 immunoreactive score was significantly higher in tumors >=4 cm in diameter (P = 0.042) and also in tumors with positive iNOS staining scores (P = 0.034; Table 2Citation ). With the Spearman rank correlation coefficient test, there was a significant (P = 0.046) positive correlation between iNOS and COX-2 expression.


View this table:
[in this window]
[in a new window]
  		Table 2 Relationship between COX-2 expression and clinicopathological factors in anti-HCV-positive HCC (n = 55)

 
MVD by Anti-CD34 Expression.
The staining of sinusoid-like vessels inside and around the tumors was evident by anti-CD34 antibody (Fig. 1E)Citation . In the surrounding liver tissue, anti-CD34 staining was confined to vessels of the portal triad with weak staining in a few of sinusoids at the periportal area. We found no relationship between tumor CD34 expression and clinicopathological factors except for capsule formation. Significantly higher numbers of tumors with capsule formation had a higher MVD than did tumors without any capsule (data not shown). In HCV-positive cases, a significant positive correlation was found between MVD and COX-2 expression (P = 0.010; Fig. 2Citation ).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2. Significant (P = 0.010, Spearman rank correlation coefficient test) positive correlation between COX-2 expression and MVD (percentage of area) was found in the HCV-positive HCCs.

 
Univariate and Multivariate Analysis of Prognostic Factors.
Neither iNOS nor COX-2 expression had any impact on patient survival when evaluated in all cases (data not shown). However, in HCV-positive HCC cases, patients with combined negative expression of iNOS and COX-2 had significant improvement in survival when compared with rest of the patients with variable expressions of iNOS and/or COX-2 (P = 0.041 and 0.018, log-rank test for overall and recurrence-free survival rates, respectively; Fig. 3Citation ). A total of five factors in the univariate analysis had significant effects on overall survival: age (<60 versus >=60 years), combined iNOS and COX-2 expression (positive group versus negative group), liver cirrhosis, serum {alpha}-fetoprotein (<100 ng/ml versus >=100 ng/ml), and differentiation (well, moderate versus others). Four factors also had prognostic impact on recurrence-free survival: age (<60 versus >=60 years), combined iNOS and COX-2 expression (positive group versus negative group), liver cirrhosis, and {alpha}-fetoprotein (<100 ng/ml versus >=100 ng/ml). Combined iNOS and COX-2 expression in HCV-positive HCC cases remained an independent prognostic factor both in the recurrence-free and overall survival analyses (Table 3)Citation .



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 3. Impact of iNOS and COX-2 expression on the survival of HCV-positive HCC patients as evaluated by the Kaplan-Meier method. Patients with both iNOS- and COX-2-negative HCCs had a significantly better overall (A) and recurrence-free (B) survival rate.

 

View this table:
[in this window]
[in a new window]
  		Table 3 Univariate and multivariate analysis of prognostic factors in HCV-positive HCC patients as evaluated by overall and recurrence-free survival

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Angiogenesis is a prerequisite for development and growth of different human tumors. For HCC, there are only few studies describing the mechanisms of microvessel formation. Although there are some studies addressing the role of COX-2 in angiogenesis (20) , there is no report describing the relationship of angiogenesis and COX-2 expression in HCC. In both the experimental setting and clinical studies, it has been shown that COX-2 induces angiogenesis, which in turn aids tumor growth, invasion, and metastasis (10) . Uefuji et al. (21) reported that COX-2 overexpression in gastric cancer samples was associated with enhanced angiogenesis. Recently, we reported that COX-2 expression correlated with tumor neovascularization in human colorectal carcinoma (22) . Very recently, it was reported that iNOS and COX-2 were positively correlated with vascular endothelial growth factor and that expression of both of these factors induced angiogenesis in non-small cell lung cancers (23) . In this study, we found that COX-2 overexpression had a strong correlation with MVD and tumor size in HCV-positive HCC cases. Recent evidence indicates that COX-2 modulates angiogenesis either by augmenting the release of angiogenic peptides (vascular endothelial growth factor, basic fibroblast growth factor, and NO) by tumor cells or by directly increasing the production of prostaglandins (10 , 24) . In this study, COX-2 expression was higher in tumors >=4 cm in diameter in HCV-positive HCCs. COX-2 expression is also significantly higher in larger tumors in colorectal cancer (25) . Prostanoid levels in adenomas from patients with familial adenomatous polyposis are significantly elevated with increased tumor size (26) . Perhaps a similar mechanism is responsible for higher COX-2 expression in larger HCCs.

We have found positive correlations between COX-2 and iNOS expression and MVD in HCV-positive HCCs. This suggests that both iNOS and COX-2 might be important factors in the pathogenesis of HCV-positive HCCs. Higher expressions of the iNOS and COX-2 genes in HCV-positive HCCs might be caused by a secondary effect of cytokines produced in response to HCV infection (27 , 28) or by the direct activation of the HCV core protein (29) . In particular, both genes have nuclear factor {kappa}B binding sites in their promoter regions (29) , and HCV is known to stimulate the activation of nuclear factor {kappa}ß (30) . Evidence suggests that iNOS is capable of inducing COX-2 expression, and there is a possibility of cross-talk between the iNOS and COX-2 systems, producing a synergistic effects in tumorigenesis (15) .

It has been reported that HCV infection causes elevated iNOS transcription (31) . Kane et al. (32) showed a significant up-regulation of iNOS in HCV-positive hepatitis and suggested that enhanced iNOS expression might be responsible for carcinogenesis in HCV-positive chronic hepatitis. We also found higher positive iNOS expression in HCV-positive HCC cases. In our study, iNOS expression was significantly higher in the surrounding liver in cirrhotic patients. In addition, it has been reported that iNOS expression becomes higher in cirrhotic liver in animal models (33) . It has been suggested that in cirrhosis, the endotoxemia and/or the increased circulating levels of cytokines may induce iNOS expression. Aberrant iNOS expression may be one of the phenotypical changes associated with the carcinogenic process in the cirrhotic liver. It might also be possible that the increased iNOS expression in the surrounding cirrhotic liver was induced by some factors released by the tumor itself. Another interesting finding of this study was a negative correlation, although not statistically significant, between iNOS expression and the serum AFP level. It was reported that the transgenic mice that expressed and produced human AFP had significantly reduced production of IFN-{gamma} in their livers and sera. (34) . IFN-{gamma} induces iNOS; it therefore might be possible that higher AFP-secreting tumors down-regulate iNOS production through IFN-{gamma}. In addition, reduced plasma nitrite/nitrate levels were reported in AFP-positive patients compared with AFP-negative patients (35) .

The biological significance of high iNOS and COX-2 expression remains controversial and poorly understood in cancers. Most of the studies indicate that high concentrations of NO and prostanoids can be either mutagenic or tumorigenic and that these effects depend on their concentrations (36 , 37) . iNOS and COX-2 expression is up-regulated in different types of premalignant and malignant lesions (3, 4, 5 , 8) . Both iNOS and COX-2 are abundantly expressed in premalignant Barrett’s esophagus (12) and in H. pylori-related gastritis (13) . We could not find any impact of iNOS and COX-2 expression on disease-free survival in all patients, but in HCV-positive cases, patients with negative expression of both iNOS and COX-2 had a significant survival advantage over the rest of the patients with variable expression of iNOS and/or COX-2. Recently, Kondo et al. (38) reported that overexpression of COX-2 in the surrounding liver was associated with a shorter disease-free survival in patients with HCV-positive HCCs.

HCC is the leading cancer in men in Taiwan and is one of the most common causes of malignancy-related death in Africa and Asia (39) . Unfortunately, to date, there is no effective preventive measure for this highly malignant disease. Many reports have indicated that COX-2 is up-regulated in most human tumors (20) . The clinical data of this study indicate that COX-2 expression may play a role in tumor angiogenesis because a direct correlation between the COX-2 expression score and MVD was observed in HCV-positive HCC cases. Recently, we have shown that COX-2 inhibitors induce growth arrest and apoptosis in several HCC-derived cell lines (40) . All of these findings indicate that COX-2 inhibitors might be effective in prevention of both cancer development and disease progression of HCC. Further research in this direction may elucidate the roles of iNOS and COX-2 in the development of HCC, which may form the basis for future novel therapeutic and/or preventive strategies to inhibit these genes.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Second Department of Surgery, Shimane Medical University, Izumo 693-8501, Japan. Phone: (81) 853-202235; Fax: (81) 853-202229; E-mail: rahman{at}shimane-med.ac.jp Back

2 The abbreviations used are: NOS, nitric oxide synthase; iNOS, inducible NOS; COX, cyclooxygenase; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; AFP, {alpha}-fetoprotein; MVD, microvessel density. Back

Received 10/18/00; revised 1/30/01; accepted 2/ 2/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Demple B., Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem., 63: 915-948, 1994.[CrossRef][Medline]
  2. Michel T., Feron O. Perspective series: nitric oxide and nitric oxide synthases. J. Clin. Investig., 100: 2146-2152, 1997.[Medline]
  3. Ambs S., Merriam W. G., Bennett W. P., Felley-Bosco E., Ogunfusika M. O., Oser S. M., Klein S., Shields P. G., Billiar T. R., Harris C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res., 58: 334-341, 1998.[Abstract/Free Full Text]
  4. Klotz T., Bloch W., Volberg C., Engelmann U., Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer (Phila.), 82: 1897-1903, 1998.[CrossRef][Medline]
  5. Swana H. S., Smith S. D., Perrotta P. L., Saito N., Wheeler M. A., Weiss R. M. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol., 161: 630-634, 1999.[CrossRef][Medline]
  6. Vane J. R., Bakhle Y. S., Botting R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38: 97-120, 1998.[CrossRef][Medline]
  7. McAdam B. F., Mardini I. A., Habib A., Burke A., Lawson J. A., Kapoor S., FitzGerald G. A. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Investig., 105: 1473-1482, 2000.[Medline]
  8. Williams C. S., Tsujii M., Reese J., Dey S. K., DuBois R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Investig., 105: 1589-1594, 2000.[Medline]
  9. McGinty A., Chang Y. W., Sorokin A., Bokemeyer D., Dunn M. J. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J. Biol. Chem., 275: 12095-12101, 2000.[Abstract/Free Full Text]
  10. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.[CrossRef][Medline]
  11. Nogawa S., Forster C., Zhang F., Nagayama M., Ross M. E., Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc. Natl. Acad. Sci. USA, 95: 10966-10971, 1998.[Abstract/Free Full Text]
  12. Wilson K. T., Fu S., Ramanujam K. S., Meltzer S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res., 58: 2929-2934, 1998.[Abstract/Free Full Text]
  13. Fu S., Ramanujam K. S., Wong A., Fantry G. T., Drachenberg C. B., James S. P., Meltzer S. J., Wilson K. T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology, 116: 1319-1329, 1999.[CrossRef][Medline]
  14. Jaiswal M., LaRusso N. F., Burgart L. J., Gores G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res., 60: 184-190, 2000.[Abstract/Free Full Text]
  15. Tomasz A. S., Jane A. M., Timothy D. W., Regina M. B., John R. V. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br. J. Pharmacol., 114: 1335-1342, 1995.[Medline]
  16. Nagasue N., Khono H., Chang Y., Taniura H., Yamanoi A., Uchida M., Kimoto T., Takemoto Y., Nakamura T., Yukaya H. Liver resection for hepatocellular carcinoma: results of 229 consecutive patients during 11 years. Ann. Surg., 217: 375-384, 1993.[Medline]
  17. Nagasue N., Ohmori H., Yamanoi A., Dhar D. K., El-Assal O. N., Yamamoto A. Different intrahepatic recurrence rate after resection of hepatocellular carcinoma associated with chronic hepatitis B and C. Hepatology Res., 12: 93-110, 1998.
  18. Koomagi R., Volm M. Expression of fas (CD95/APO-1) and fas ligand in lung cancer, its prognostic and predictive relevance. Int. J. Cancer, 84: 239-243, 1999.[CrossRef][Medline]
  19. Sidney S., Salmon E., Quatrano R. Digital photography for the light microscope: results with a gated. Video-rate CCD camera and NIH-image software. Biotechniques, 19: 946-955, 1995.[Medline]
  20. Masferrer J. L., Leahy K. M., Koki A. T., Zweifel B. S., Settle S. L., Woerner B. M., Edwards D. A., Flickinger A. G., Moore R. J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.[Abstract/Free Full Text]
  21. Uefuji K., Ichikura T., Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res., 6: 135-138, 2000.[Abstract/Free Full Text]
  22. Masunaga R., Kohno H., Dhar D. K., Ohno S., Shibakita M., Kinugasa S., Yoshimura H., Tachibana M., Kubota H., Nagasue N. COX-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res., 6: 4064-4068, 2000.[Abstract/Free Full Text]
  23. Marrogi A. J., Travis W. D., Welsh J. A., Khan M. A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N. E., Liotta L. A., Harris C. C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res., 6: 4739-4744, 2000.[Abstract/Free Full Text]
  24. Chiarugi V., Magnelli L., Gallo O. Cox-2, iNOS, and p53 as play-markers of tumor angiogenesis. Int. J. Mol. Med., 2: 715-719, 1998.[Medline]
  25. Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M. M., Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 in human colorectal carcinoma. Cancer Res., 58: 4823-4826, 1998.[Abstract/Free Full Text]
  26. Yang V. W., Shields J. M., Hamilton S. R., Spannhake E. W., Hubbard W. C., Hylind L. M., Robinson C. R., Giardiello F. M. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res., 58: 1750-1753, 1998.[Abstract/Free Full Text]
  27. Schweyer S., Mihm S., Radzun H. J., Hartmann H., Fayyazi A. Liver infiltrating T lymphocytes express interferon {gamma} and inducible nitric-oxide synthase in chronic hepatitis C virus infection. Gut, 46: 255-259, 2000.[Abstract/Free Full Text]
  28. Matsuura H., Sakaue M., Subbaramaiah K., Kamitani H., Eling T. E., Dannenberg A. J., Tanabe T., Inoue H., Arata J., Jetten A. M. Regulation of cyclooxygenase-2 by interferon {gamma} and transforming growth factor {alpha} in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J. Biol. Chem., 274: 29138-29148, 1999.[Abstract/Free Full Text]
  29. D’acquisto F., Lanzotti V., Carnuccio R. Cyclolinteinone, a sesterterpene from sponge Cacospongia linteiformis, prevents inducible nitric oxide synthase and inducible cyclo-oxygenase protein expression by blocking nuclear factor-{kappa} B activation in J774 macrophages. Biochem. J., 346: 793-798, 2000.
  30. Tai D. I., Tsai S. L., Chen Y. M., Chuang Y. L., Peng C. Y., Sheen I. S., Yeh C. T., Chang K. S. S., Huang S. N., Kuo G. C., Liaw Y. F. Activation of nuclear factor {kappa}B in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology, 31: 656-664, 2000.[CrossRef][Medline]
  31. Mihm S., Fayyazi A., Ramadori G. Hepatic expression of inducible nitric-oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic load and liver injury. Hepatology, 26: 451-458, 1997.[CrossRef][Medline]
  32. Kane J. M., Shears L. L., Hierholzer C., Ambs S., Billiar T. R., Posner M. C. Chronic hepatitis C virus infection in humans: induction of hepatic nitric-oxide synthase and proposed mechanism for carcinogenesis. J. Surg. Res., 69: 321-324, 1997.[CrossRef][Medline]
  33. Mizumoto M., Arii S., Furutani M., Nakamura T., Ishigami S., Monden K., Ishiguro S., Fujita S., Imamura M. NO as an indicator of portal hemodynamics and the role of iNOS in increased NO production in CCl4-induced liver cirrhosis. J. Surg. Res., 70: 124-133, 1997.[CrossRef][Medline]
  34. Yamashita T., Nakane A., Watanabe T., Miyoshi I., Kasai N. Evidence that {alpha}-fetoprotein suppresses the immunological function in transgenic mice. Biochem. Biophys. Res. Commun., 201: 1154-1159, 1994.[CrossRef][Medline]
  35. Moriyama A., Tabaru A., Unoki H., Abe S., Masumoto A., Otsuki M. Plasma nitrite/nitrate concentrations as a tumor marker for hepatocellular carcinoma. Clin. Chim. Acta, 296: 181-191, 2000.[CrossRef][Medline]
  36. Sandhu J. K., Privora H. F., Wenckebach G., Birnboim H. C. Neutrophils, nitric-oxide synthase, and mutations in the mutatect murine tumor model. Am. J. Pathol., 156: 509-518, 2000.[Abstract/Free Full Text]
  37. Battu S., Rigaud M., Beneytout J. L. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res., 18: 3579-3583, 1998.[Medline]
  38. Kondo M., Yamamoto H., Nagano H., Okami J., Ito Y., Shimizu J., Eguchi H., Miyamoto A., Dono K., Umeshita K., Matsuura N., Sakon M., Monden M. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res., 5: 4005-4012, 1999.[Abstract/Free Full Text]
  39. London W. T. Primary hepatocellular carcinoma: aetiology, pathogenesis, and prevention. Hum. Pathol., 12: 1085-1097, 1981.[Medline]
  40. Rahman M. A., Dhar D. K., Masunaga R., Yamanoi A., Kohno H., Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res., 60: 2085-2089, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
D. F. Calvisi, F. Pinna, S. Ladu, R. Pellegrino, M. R. Muroni, M. M. Simile, M. Frau, M. L. Tomasi, M. R. De Miglio, M. A. Seddaiu, et al.
Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease
Carcinogenesis, August 1, 2008; 29(8): 1639 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y. Kawano, A. Sasaki, S. Kai, Y. Endo, K. Iwaki, H. Uchida, K. Shibata, M. Ohta, and S. Kitano
Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis
Ann. Surg. Oncol., June 1, 2008; 15(6): 1670 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A. P Holt and D. H Adams
Complex roles of cyclo-oxygenase 2 in hepatitis
Gut, July 1, 2007; 56(7): 903 - 904.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Yu, X. Sun, Y. Qiu, J. Zhou, Y. Wu, L. Zhuang, J. Chen, and Y. Ding
Identification and Clinical Significance of Mobilized Endothelial Progenitor Cells in Tumor Vasculogenesis of Hepatocellular Carcinoma
Clin. Cancer Res., July 1, 2007; 13(13): 3814 - 3824.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Y. Chung, J. H. Park, M. J. Kim, H. O. Kim, J. K. Hwang, S. K. Lee, and K. K. Park
Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-{kappa}B
Carcinogenesis, June 1, 2007; 28(6): 1224 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Fantappie, M. Solazzo, N. Lasagna, F. Platini, L. Tessitore, and R. Mazzanti
P-Glycoprotein Mediates Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines
Cancer Res., May 15, 2007; 67(10): 4915 - 4923.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Xu, C. Han, K. Lim, and T. Wu
Cross-talk between Peroxisome Proliferator-Activated Receptor {delta} and Cytosolic Phospholipase A2{alpha}/Cyclooxygenase-2/Prostaglandin E2 Signaling Pathways in Human Hepatocellular Carcinoma Cells
Cancer Res., December 15, 2006; 66(24): 11859 - 11868.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Lasagna, O. Fantappie, M. Solazzo, L. Morbidelli, S. Marchetti, G. Cipriani, M. Ziche, and R. Mazzanti
Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.
Cancer Res., March 1, 2006; 66(5): 2673 - 2682.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. Waris and A. Siddiqui
Hepatitis C Virus Stimulates the Expression of Cyclooxygenase-2 via Oxidative Stress: Role of Prostaglandin E2 in RNA Replication
J. Virol., August 1, 2005; 79(15): 9725 - 9734.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ueno, D. Aoki, F. Kubo, K. Hiwatashi, K. Matsushita, T. Oyama, I. Maruyama, and T. Aikou
Roxithromycin Inhibits Constitutive Activation of Nuclear Factor {kappa}B by Diminishing Oxidative Stress in a Rat Model of Hepatocellular Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5645 - 5650.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Wang, A. Bergh, and J.-E. Damber
Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3250 - 3256.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. FODERA, N. D'ALESSANDRO, A. CUSIMANO, P. POMA, M. NOTARBARTOLO, N. LAMPIASI, G. MONTALTO, and M. CERVELLO
Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX-2 Inhibitors
Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 440 - 449.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. A. Rue, M. A. Jarvis, A. J. Knoche, H. L. Meyers, V. R. DeFilippis, S. G. Hansen, M. Wagner, K. Fruh, D. G. Anders, S. W. Wong, et al.
A Cyclooxygenase-2 Homologue Encoded by Rhesus Cytomegalovirus Is a Determinant for Endothelial Cell Tropism
J. Virol., November 15, 2004; 78(22): 12529 - 12536.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-H. Hung, I.-J. Su, H.-Y. Lei, H.-C. Wang, W.-C. Lin, W.-T. Chang, W. Huang, W.-C. Chang, Y.-S. Chang, C.-C. Chen, et al.
Endoplasmic Reticulum Stress Stimulates the Expression of Cyclooxygenase-2 through Activation of NF-{kappa}B and pp38 Mitogen-activated Protein Kinase
J. Biol. Chem., November 5, 2004; 279(45): 46384 - 46392.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Machida, K. T.-H. Cheng, V. M.-H. Sung, K. J. Lee, A. M. Levine, and M. M. C. Lai
Hepatitis C Virus Infection Activates the Immunologic (Type II) Isoform of Nitric Oxide Synthase and Thereby Enhances DNA Damage and Mutations of Cellular Genes
J. Virol., August 15, 2004; 78(16): 8835 - 8843.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L Messerini, L Novelli, and C E Comin
Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma
J. Clin. Pathol., August 1, 2004; 57(8): 867 - 871.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Cianchi, C. Cortesini, O. Fantappie, L. Messerini, I. Sardi, N. Lasagna, F. Perna, V. Fabbroni, A. Di Felice, G. Perigli, et al.
Cyclooxygenase-2 Activation Mediates the Proangiogenic Effect of Nitric Oxide in Colorectal Cancer
Clin. Cancer Res., April 15, 2004; 10(8): 2694 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-S. Chun, H.-H. Cha, J.-W. Shin, H.-K. Na, K.-K. Park, W.-Y. Chung, and Y.-J. Surh
Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-{kappa}B
Carcinogenesis, March 1, 2004; 25(3): 445 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Davies, L.-A. Martin, N. Sacks, and M. Dowsett
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention
Ann. Onc., May 1, 2002; 13(5): 669 - 678.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahman, Md. A.
Right arrow Articles by Nagasue, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahman, Md. A.
Right arrow Articles by Nagasue, N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online